IFNB1 and myeloid sarcoma: Our results indicate that no such effect is associated with fingolimod, but did reveal a strong and specific increase of ceramides of specific chain lengths especially in IFN-β-treated MS patients, compared to healthy controls, untreated patients or other treatment groups (Figures 1 and 2).